A wide range of estimates has been provided on the potential costs of pharmaceutical changes under the intellectual property provisions of the act. There has been a number of those sets of analyses. It's extremely difficult work. In fact, we don't believe the estimates we would be able to provide would meaningfully advance the issues, because we have no foresight as to the nature of the drugs that will potentially be on the market, post the coming into force, for those that would actually benefit from a certificate of supplementary protection, for instance. It's impossible to know which patent will be selected and on which drugs, so to our end it would be nearly impossible to predict what the specifics of the impacts would be.
On December 14th, 2016. See this statement in context.